The Globe and Mail
🏢 Globe and Mail Inc. (Woodbridge)
Jun 30, 2026
· 8 min read
AI Analyzed
○ Unverifiable
View full audit trail →
Despite approval from Health Canada, delay in cancer drug funding leaves patients in limbo
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
-0.40 · CENTER
ML v2 (DistilBERT)
0.296 · RIGHT
Ensemble
0.148 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.105
10,354 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
Despite approval from Health Canada, delay in cancer drug funding leaves patients in limbo
KELLY GRANT
PUBLISHED JUNE 30, 2026
UPDATED JULY 7, 2026
Open this photo in gallery:
Alex Shved and his wife Agata Zieba, parents to two daughters under two years old, are appealing OHIP’s decision to deny Shved's out-of-country coverage that would allow him to access tumour-infiltrating lymphocyte (TIL) therapy in the U.S. The couple is seen at their home in Toronto, on June 18.
GALIT RODAN/THE GLOBE AND MAIL
COMMENTS
SHARE
SAVE FOR LATER
Listen to this article
Learn more about audio
Log in or crea…
Read full article at The Globe and Mail ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1 + full
Jul 26, 2026